Pharmafile Logo
Pharmafocus logo
Advanced Search

Almirall

Showing 15 posts of 25 posts found.

Almirall licenses Novo Nordisk’s anti-IL-21 monoclonal antibody for dermatology treatment

February 23, 2024
Research and Development Almirall, Dermatology, Novo Nordisk, dermatology, monoclonal antibody

Almirall has announced that it has entered into an exclusive license agreement with Novo Nordisk for the rights to its …

News

Almirall gains EC approval of Ebglyss for moderate-to-severe atopic dermatitis

November 20, 2023
Medical Communications Almirall, Dermatology, Ebglyss, European Commission, atopic dermatitis

Almirall has announced that the European Commission (EC) has approved Ebglyss (lebrikizumab) for the treatment of adult and adolescent patients …

News

Almirall: The New England Journal of Medicine (NEJM) and the British Journal of Dermatology (BJD) publish Ph3 data evaluating lebrikizumab efficacy and safety in moderate-to-severe atopic dermatitis

March 31, 2023
Business Services Almirall, Dermatology, dermatology, lebrikizumab

BARCELONA, Spain. March 31, 2023 – Almirall, S.A. (ALM), a global biopharmaceutical company focused on medical dermatology, announced today the …

News
Press release
almirall-605x338

MC2 Therapeutics grants Almirall European commercial rights for psoriasis cream Wynzora

February 18, 2021
Almirall, MC2 Therapeutics, psoriasis

Biopharma company Almirall and MC2 Therapeutics, a pharmaceutical company focused on therapies for autoimmune and chronic inflammatory conditions, have announced …

News

NICE approves Cimzia but blocks Ilumetri in treatment of psoriasis

December 4, 2018
Manufacturing and Production, Sales and Marketing Almirall, Cimzia, Ilumetri, NICE, UCB, UK, pharma, psoriasis

UK drug watchdog NICE has announced two new recommendations relating to medicines for the treatment of psoriasis, approving UCB Pharma’s …

News
almirall-605x338

Almirall’s Ilumetri scores EU approval in chronic plaque psoriasis

September 19, 2018
Research and Development, Sales and Marketing Almirall, EADV 2018, Ilumetri, pharma, psoriasis

Hot on the heels of the European Academy of Dermatology and Venereology Congress (EADV) 2018 where psoriasis took centre stage, …

News
allergan

Almirall picks up Allergan’s dermatology portfolio to for $650m

August 3, 2018
Medical Communications, Sales and Marketing Allergan, Almirall, dermatology, pharma

Allergan has sealed a deal to sell its dermatology portfolio, comprising five brands, to Spanish pharmaceutical firm Almirall for $650 …

News
governance_guenterpeter

EVP of Diabetes decamps from Sanofi to become Almirall CEO

August 30, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Almirall, Sanofi, biotech, drugs, pharma, pharmaceutical

Sanofi’s Executive Vice President of Diabetes & Cardiocascular, Peter Guenter, has opted to end his 22-year-long stay at the company …

Appointment
nice_new_london_office_internal_3_web

NICE recommends plaque psoriasis contender for NHS use

August 8, 2017
Manufacturing and Production, Sales and Marketing Almirall, NICE< Skilarence, drugs, life sciences, medicine, pharma, pharmaceuticals, plaque psoriasis, psoriasis

The use of Almirall’s psoriasis drug Skilarence (dimethyl fumarate) on the UK’s NHS is one step closer after NICE gave …

News
alm_v2

Grünenthal Group to acquire Almirall’s Mexico unit for about €50 million

March 17, 2016
Business Services, Sales and Marketing Almirall, Grünenthal Group, merger and acquisition

Privately-held Grünenthal Group said it has signed a definitive agreement to buy Almirall Group’s Mexico-based business for about €50 million ,to …

News
Almirall logo

Almirall to acquire Poli Group’s skin drugs

November 30, 2015
Sales and Marketing Almirall, Poldi, dermatology, skin, specialty pharma

Almirall has agreed to acquire 100% of the share capital of Poli Group Holding as the Spanish pharma company continues …

News
sativex

Almirall presents new data on cannabinoid-based MS treatment

October 9, 2015
Research and Development Almirall, multiple sclerosis

Almirall has presented new clinical evidences of Sativex, the only medicine derived from cannabinoids to treat spasticity symptoms in MS, …

News

AstraZeneca completes respiratory deal with Almirall

November 3, 2014
Research and Development, Sales and Marketing Almirall, AstraZeneca, Pfizer, deal, duaklir, merger, respiratory

AstraZeneca has finally completed its takeover of Almirall’s respiratory drug portfolio in a deal worth $875 million. As reported by …

News

AstraZeneca secures respiratory drugs from Almirall

July 30, 2014
Research and Development, Sales and Marketing Almirall, AstraZeneca, Pfizer, Symbicort, lung drugs

AstraZeneca has paid $875 million to take control of Alimirall’s respiratory drug portfolio that includes treatments for bronchitis and emphysema. …

News
03_dorrepaal_karin_dr_01

Almirall appoints first woman to its Board

November 21, 2012
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Almirall

Karin Louise Dorrepaal is the first woman to join Almirall’s ten-member Board of directors. Dorrepaal, who is Dutch, has extensive …

Appointment

Latest content

Sanofi shares results for phase 3 LUNA 3 trial in immune thrombocytopenia

April 23, 2024

FDA approves ImmunityBio’s Anktiva bladder cancer treatment

April 23, 2024

EC approves Pfizer’s Emblaveo for multidrug-resistant infection treatment

April 22, 2024

Neurolentech and Kaerus Bioscience enter partnership for research on neurodevelopmental disorder

April 22, 2024

Ardena announces €20m expansion following first GMP approval

April 19, 2024